Asure Announces Third Quarter 2026 Results

Asure Software reported Q3 2026 revenue of $40.0 million, up 10% year over year, and recurring revenue of $36.9 million, up 16%. Net loss narrowed to $0.6 million from $5.4 million, while adjusted EBITDA rose to $10.5 million from $8.1 million and non-GAAP gross margin expanded to 75% from 70%. For the first nine months, revenue increased 18% to $119.9 million and net loss narrowed to $4.4 million from $13.9 million.

Analysis

The quality of growth is improving, but the headline growth rate overstates the change in underlying demand: on the reported figures, revenue outside the recurring category declined year over year in Q3, assuming the categories are consistently defined. That mix shift supports a more predictable revenue base, while also flagging possible softness in implementation, services, or other nonrecurring activity that could limit total growth. The gross-margin expansion and stronger EBITDA indicate operating leverage; however, the remaining gap between adjusted EBITDA and GAAP results means investors should verify cash conversion and the sources of adjustments before capitalizing the improvement as durable.

Near term, the release supports a positive read-through for ASUR, but it does not establish whether recurring growth is organic, acquisition-supported, or sustainable, and provides no guidance, cash-flow, or balance-sheet detail. Over 1–3 months, those disclosures—and evidence that nonrecurring revenue stabilizes—matter more than the reported adjusted EBITDA step-up. Over 6–18 months, continued recurring growth with margin gains could improve the company’s quality multiple; a deceleration would leave the smaller HCM provider exposed to larger competitors such as ADP, Paylocity, and Paycom. The contrarian risk is that investors may treat a single-quarter margin improvement as structural before validating cash generation and revenue mix.

Key Decisions for Investors

• Do not chase ASUR solely on the adjusted EBITDA improvement. Consider a starter long only after reviewing the full filing and management commentary for organic recurring growth, cash conversion, and the outlook; the release alone does not establish valuation or balance-sheet risk/reward.
• Track the next quarter’s recurring growth alongside nonrecurring revenue and gross margin. A recurring-growth slowdown or further nonrecurring contraction would falsify the improving-quality thesis; stable recurring growth and sustained margins would strengthen it.
• Use the full results and subsequent guidance as the 1–3 month catalyst check: verify free cash flow, the reconciliation of adjusted to GAAP results, and any acquisition contribution before adding exposure.
• Treat any initial positive reaction as vulnerable to reversal if management lowers growth or margin expectations, or if cash generation fails to track EBITDA. No peer short or options position is warranted from these figures alone.